관련문헌 등
·Harrison's Principles of Internal Medicine, 20e.
·Goldman-Cecil Medicine, 25e.
·Bradley’s neurology in Clinical Practice, 7e.
·최신정신의학 제6판, 민성길, 2015.
·신경학. 대한신경과학회. 2012.
·NHMRC guideline. Clinical Practice Guidelines and Principles of Care for People with Dementia.
·BAP Guideline. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology 2017.
·EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. European Journal of Neurology 2012, 19: 1159？1179.
·SIGN guideline. Diagnosis and pharmacological management of Parkinson’s disease. (January 2010)
·APA Guideline. Treatment of Patients With Alzheimer’s Disease and Other Dementias. Second edition. (Published: October 2007)
·치매임상진료지침. 보건복지부 지정 노인성치매 임상연구센터. 2011.
·NICE guideline. Parkinson’s disease in adults. NG71.(Published: 19 July 2017)
·NICE guideline. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. TA217. (Published: 23 March 2011)
·NICE guideline. Dementia: Assessment, management and support for people living with dementia and their carers. NG97. (Published: 03 January 2018).
·Rolinski M, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease (Review). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD006504.
·Murat Emre, et al. Rivastigmine for Dementia Associated with Parkinson’s Disease. N Engl J Med 2004;351:2509-18.
·Werner Poewe, et al. Long-Term Benefits of Rivastigmine in Dementia Associated With Parkinson’s Disease: An Active Treatment Extension Study. Mov Disord. 2006 Apr;21(4):456-61.
·Murat Emre, et al. Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study. Clin Neuropharm 2014;37: 9？16.
·Sam T Creavin, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD011145.
·Alex J. Mitchell, et al. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. Jouranl of Psychiatric Research 43(2009) 411-431.
·Ziad S. Nasreddine, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc 53:695？699, 2005.
·Lin JS, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force. Rockville(MD): Agency for Healthcare Research and Quality(US); 2013 Nov.
·Kelvin K. F. Tsoi, et al. Cognitive Tests to Detect Dementia A Systematic Review and Meta-analysis. JAMA Intern Med. Published online June 8, 2015.
·Paula T. Trzepacz, et al. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatrics (2015) 15:107.
·Ji In Kim, et al. The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson’s Disease. J Mov Disord 2016;9(3):152-159.
·Ciaran O’Driscoll, et al. Cross-Cultural Applicability of the Montreal Cognitive Assessment(MoCA): A Systematic Review. J Alzheimers Dis. 2017;58(3):789-801.